MARKER THERAPEUTICS (MRKR)
(Delayed Data from NSDQ)
$5.40 USD
+0.56 (11.57%)
Updated Jul 24, 2024 03:59 PM ET
After-Market: $5.53 +0.13 (2.41%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.40 USD
+0.56 (11.57%)
Updated Jul 24, 2024 03:59 PM ET
After-Market: $5.53 +0.13 (2.41%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Zacks News
MARKER THERAPEUTICS, INC. (MRKR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
MARKER THERAPEUTICS, INC. (MRKR) delivered earnings and revenue surprises of 38.46% and 393.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Are Options Traders Betting on a Big Move in Marker Therapeutics (MRKR) Stock?
by Zacks Equity Research
Investors need to pay close attention to Marker Therapeutics (MRKR) stock based on the movements in the options market lately.
Do Options Traders Know Something About Marker Therapeutics (MRKR) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Marker Therapeutics (MRKR) stock based on the movements in the options market lately.
Will Marker Therapeutics Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Marker Therapeutics.
MARKER THERAPEUTICS, INC. (MRKR) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
MARKER THERAPEUTICS, INC. (MRKR) delivered earnings and revenue surprises of 7.69% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured expert Kevin Matras highlights: Methode Electronics, Walker & Dunlop, Marker Therapeutics, Chemed and Olympic Steel
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Methode Electronics, Walker & Dunlop, Marker Therapeutics, Chemed and Olympic Steel
These 5 Stocks Make Great Buys on New Analyst Coverage
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.